

Uptake of dopamine by rat hepatocytes *in vitro*

HONG Zhi-Duan, Simone WATTIAUX-DE CONINCK, Robert WATTIAUX¹
 (Laboratoire de Chimie Physiologique, Faculté de Médecine, Facultés Universitaires,
 Notre-Dame de la Paix, B-5000 Namur, Belgium)

ABSTRACT The present results showed that uptake of dopamine (DA) by rat isolated hepatocytes was mediated, in addition to simple diffusion, mainly by a transporter-involved process, with K_m of 66.8 μmol and V_{max} of 1.3 $\text{pmol}\cdot\text{min}^{-1}/10^5$ cells. The process was pH- and temperature-dependent and required an activation energy of 4.12 $\text{kcal}\cdot\text{mol}^{-1}$ ($Q_{10}=2.5$) in the range of 2.0-12.7 $^{\circ}\text{C}$ and 13.0 $\text{kcal}\cdot\text{mol}^{-1}$ ($Q_{10}=2.0$) in the range of 12.7-20.0 $^{\circ}\text{C}$. Cysteine residue having free thiol group was unrelated to the activity of the transporter. Catecholamines, serotonin, and procaine inhibited the DA transport, but tyramine (TA) and tryptamine, as well as mazindol and imipramine (which are potent inhibitors for hepatic TA transporter and neuronal DA transporter), had no inhibitory effect on the transport of DA in these cells. These results indicated that DA was taken up into hepatocytes by a distinct carrier. NaF and mastoparan influenced the transport activity in these cells further, suggesting that signal transducing G-proteins may be involved in the regulation of DA transporter in rat hepatocytes.

KEY WORDS liver; cultured cells; dopamine; biological transport; wasp venoms

It is well established that the concentration of dopamine (DA) in brain is controlled in the intercellular space mostly by reuptake mechanisms. The neuronal DA transporters

of human⁽¹⁾ and rat⁽²⁾ have been cloned. In contrast, studies of DA transporters in extraneuronal tissues are rare except the uptake of DA in platelets which was altered in patients with Parkinson disease, schizophrenia, and Huntington's disease⁽³⁾. About 50 % of DA uptake into platelets was mediated through a serotonin carrier, while the other 50 % is possibly due to passive diffusion and low affinity uptake⁽⁴⁾.

DA is used widely for treatment of shock and heart failure. Following intravenous injection, DA is mainly cleared from plasma by extraneuronal tissues, among which liver plays an important role. As a consequence of the entry of DA into liver cells, the amine is inactivated by monoamine oxidase of the outer membrane of mitochondria. Information concerning the mechanisms by which DA is transported through the hepatic plasma membrane is not available. Recently, we have characterized a transport system in rat hepatocytes for the uptake of tyramine (TA)⁽⁵⁾. Since TA is structurally very similar to DA, we proceeded to study the DA uptake by rat isolated hepatocytes.

MATERIALS AND METHODS

Wistar rats, ♂, weighing about 200 g, were starved for 20 h before killing. Hepatocytes were isolated according to the method of Seglen⁽⁶⁾ with slight modification: both Ca^{2+} -free and collagenase perfusions were carried out at 34 $^{\circ}\text{C}$ for 6 min. Only the preparations in which >90 % of the cells excluded trypan blue were used. The cells were kept at 4 $^{\circ}\text{C}$ and within 2 h.

Unless stated otherwise in the legends of the fig-

ures, transport assays were performed in RPMI 1640 medium without serum, containing HEPES 10 mmol \cdot L $^{-1}$ (pH 7.6), at 37 C for 30 s. In this case, the amounts of [3 H]DA within the cells after incubation did not exceed 5 % of the amount added to the medium. Cells (3×10^5) were preincubated at 37 C for 2 min and then incubated with [3 H]DA 30 nmol \cdot L $^{-1}$ (specific radioactivity 1.25 TBq \cdot mol $^{-1}$) in a final volume of 200 μ l, in the absence or presence of inhibitors which were added simultaneously with the labelled TA, except when indicated in the legends. The uptake reaction was stopped by the addition of 400 μ l ice-cold medium. Samples of 200 μ l were immediately put in an Eppendorf microtube, on the top of 150 μ l oil (a mixture of dibutyl phthalate and dioctyl phthalate of 1.20 g \cdot ml $^{-1}$ density) and centrifuged at 10 000 \times g for 30 s. The cell pellet was cut and added to 0.5 ml boiling SDS solution (10 %) in a scintillation vial. After 5 min, 4 ml of a liquid-scintillation cocktail (Aqualuma Lumac, Landgraaf, The Netherlands) were added and counted in a Beckman β counter. When the effects of thiol group modifier was tested, experiments were carried out with perfusion buffer which was composed of NaCl 137, KCl 5.4, Na $_2$ HPO $_4$ \cdot 2H $_2$ O 3.4, KH $_2$ PO $_4$ 3.5, MgSO $_4$ \cdot 7H $_2$ O 8.1, NaHCO $_3$ 24.4, and CaCl $_2$ \cdot 2H $_2$ O 2.0 mmol \cdot L $^{-1}$, pH: 7.4. Buffer X $^{(7)}$ used for the determination of mastoparan $^{(7)}$ effect on DA transport in hepatocytes contains NaCl 4.74, KCl 118, CaCl $_2$ 0.38, egtazic acid 1, MgSO $_4$ 1.19, KH $_2$ PO $_4$ 1.19, sodium pyruvate 3, HEPES/KOH 25 mmol \cdot L $^{-1}$, pH: 7.4 $^{(8)}$. Experiment concerning the effects of F $^-$ on DA transport in hepatocytes was performed in HEPES buffer (20 mmol \cdot L $^{-1}$, pH: 7.4) containing NaCl 40 mmol \cdot L $^{-1}$ and different concentrations of sucrose to keep the osmolarity balance of the solution (300 mOsm \cdot L $^{-1}$). The extracellular water contamination was measured by adding [14 C]sucrose to a hepatocyte suspension before centrifugation and radioactivity determination in the cell pellet. Less than 0.3 % of the added radioactivity was present in the pellet. Thus, the contamination with extracellular water is always substantially lower ($n = 3$, 2.02 \pm 0.10 %) than the total radioactivity associated with the cell pellet in the [3 H]DA uptake experiments.

Since simple diffusion and transporter mediated processes coexist in the uptake of DA by hepatocytes, total DA transport refers to both processes involved

in transport, while DA transport refers to the transporter mediated uptake which is calculated after eliminating the simple diffusion part measured in the presence of cold DA 10 mmol \cdot L $^{-1}$.

RESULTS

Uptake kinetics of [3 H]DA [3 H]DA was incubated with isolated hepatocytes at 37 C. The accumulation of [3 H]DA in the cells was time-dependent (Fig 1). The cellular influx rates were determined as a function of DA concentration in the medium (Fig 2). The curve was biphasic and could be resolved into a linear and a hyperbolic curve with a K_m of 66.8 μ mol \cdot L $^{-1}$ and V_{max} of 523 pmol \cdot min $^{-1}$ 10^5 cells, suggesting that both simple diffusion and transporter-mediated mechanisms are involved in this uptake process.




Fig 1. [3 H]DA uptake by isolated hepatocytes incubated with [3 H]DA (30 nmol \cdot L $^{-1}$) at 37 C in RPMI 1640 medium.

Effects of temperature and extracellular pH on [3 H]DA transport [3 H]DA transport in isolated hepatocytes was temperature-dependent, requiring an activation energy (E_a) of 4.12 kcal \cdot mol $^{-1}$ and Q_{10} of 1.25 (12.7 $^{\circ}$ C) as well as a E_o of 13.0 kcal \cdot mol $^{-1}$ and Q_{10} of 2.0 (12.7 $^{\circ}$ C - 39.0 $^{\circ}$ C). The





Fig 2. $[^3\text{H}]\text{DA}$ uptake by isolated hepatocytes. The curve (a) fitting the data (\circ) can be resolved into a saturable process (c) with a K_m of $66.8 \mu\text{mol} \cdot \text{L}^{-1}$ and a V_m of $523 \text{ pmol} \cdot \text{min}^{-1}/10^5$ cells as well as a linear uptake (b); v ($\text{pmol} \cdot \text{min}^{-1}/10^5$ cells) = $5.61 \times [S]$. A': an inset from A.

$[^3\text{H}]\text{DA}$ transport was also influenced by the pH of the medium. The $[^3\text{H}]\text{DA}$ transport activity at 37°C quickly increased as the pH in the medium rose from 6.44 to 7.25, reaching a plateau after pH 7.49. The increase of $[^3\text{H}]\text{DA}$ transport at 4°C was considerably slower with increasing pH (Fig 3).




Fig 3. Effects of temperature and extracellular pH on $[^3\text{H}]\text{DA}$ uptake by hepatocytes.

Inhibition of $[^3\text{H}]\text{DA}$ transport by DA analogues and other substances Tested on $[^3\text{H}]\text{DA}$ transport in isolated hepatocytes were DA analogues and non-analogues including substances which potentially block TA transporters in rat liver cells⁽⁵³⁾ and DA transporters in brain⁽⁹³⁾, such as benztropine, imipramine, and cocaine, as well as the substances which modify the thiol group of cysteine, such as *N*-ethylmaleimide (NEM), *p*-aminophenylmercuric acetate (pAPMA), ethylmercurithiosalicylic acid (EMTSA), and iodoacetamide. We used thiol group modifiers because the activity of many transporters, such as hepatic tyramine transporters⁽⁵³⁾, depends on the cysteine residue having free thiol group within the polypeptides. The transport of $[^3\text{H}]\text{DA}$ in the hepatocytes was most potentially inhibited by cold DA, and it was also inhibited by serotonin, adrenaline, noradrenaline, and cocaine, but not by TA, tryptamine, benztropine, and imipramine (Fig 4).

On the other hand, all the thiol-group modifiers did not modify the DA transport activity in rat hepatocytes (Tab 1).

Effect of F^- and mastoparan on $[^3\text{H}]\text{DA}$ transport Prior to the transport activity assay, the cells were incubated with Buffer X and mastoparan at 4°C for 90 min immediate-




Fig 4. Effects of substances on uptake of [³H]DA by hepatocytes. *n* = 3, $\bar{x} \pm s$.

Tab 1. Effects of amino acid modifiers on uptake of [³H]DA by 3×10^6 hepatocytes incubated in 2-ml perfusion buffer (pH: 7.6) at 25 °C for 30 min. Then the cells were washed twice with 5-ml perfusion buffer at 4 °C before transport assay *n* = 2.

Modifier	Concentration/ mmol · L ⁻¹	[³ H]DA transport/ % of control (120 fmol)
NEM	1	95
pAPMA	1	99
EMTSA	1	125
Iodoacetamide	1	111

ly after the purification. As shown in Tab 2, mastoparan (80 $\mu\text{mol} \cdot \text{L}^{-1}$) induced considerable inhibition of the DA transport, $42 \pm 1.7\%$ activity remained as compared with the control (Tab 2).

We also determined the influence on DA transport of F^- , which modulates the activity of adenylyl cyclase as the results of interaction of the anion with all G^- proteins⁽¹⁰⁾. F^-

Tab 2. Effects of mastoparan on [³H]DA uptake in hepatocytes incubated in X buffer at 4 °C for 90 min. *n* = 3, $\bar{x} \pm s$. ^a*P* > 0.05, ^b*P* < 0.01 vs control.

Mastoparan/ $\mu\text{mol} \cdot \text{L}^{-1}$	[³ H]DA transport fmol	% of control
0 (control)	301 ± 23	100 ± 7.6
3.8	263 ± 5 ^a	87 ± 1.7 ^a
80	127 ± 5 ^b	42 ± 1.7 ^b

increased the DA transport activity. The maximal activity (330 % of the control) was caused by NaF 20 $\text{mmol} \cdot \text{L}^{-1}$. As the F^- concentration increased further, the transport activity decreased (Fig 5).




Fig 5. Effects of F^- on [³H]DA transport in hepatocytes.

DISCUSSION

The clearance of DA in general circulation depends on the uptake processes of extra-neuronal tissues, among which liver is an important organ. However, the mechanism by which DA is taken up by liver has never been reported. The work presented here demonstrated that the transport of DA in isolated hepatocytes is mediated by a transporter-involved process in addition to simple diffusion. The physiological significance of this transport

em is suggested by the following observa-
s. When the concentration of DA in
ium was $<25 \mu\text{mol}\cdot\text{L}^{-1}$, the carrier-medi-
process was the main mechanism for the
ke of DA by hepatocytes (Fig 2). This
within the range of DA concentration in
ma of patients receiving intravenous injec-
of DA for the treatment of shock ($3.4 -$
 $4 \mu\text{mol}\cdot\text{L}^{-1}$)^(11,12) or heart failure ($0.17 -$
 $4 \mu\text{mol}\cdot\text{L}^{-1}$)⁽¹³⁾. Under the unsaturated
centration ($30 \text{ nmol}\cdot\text{L}^{-1}$), 72 % - 82 % of
[DA was captured through a transporter-
ated process and 18 % - 28 % was taken
simple diffusion (Fig 4). Even in the
ence of high concentration of cold DA (10
 $\text{ol}\cdot\text{L}^{-1}$), a small proportion of [³H]DA
still represent nonspecific binding. The
proportion of [³H]DA taken up by free
usion should be lower than the above -
ationed values.

For TA transport in isolated rat hepato-
s both simple diffusion and transporter-
ated processes are involved in the uptake
TA⁽⁵⁾. Are TA and DA taken up into rat
atocytes by the same carrier? Our results
est 2 separate carriers are involved. This
clusion is supported by the following
ence;

1) DA potentially inhibits [³H]TA trans-
in hepatocytes. In contrast, TA has no
bitory effect on the [³H]DA transport in
e cells. Apparently, although DA has a
affinity for the TA transporter in these
. Apparently, although DA has a high
ity for the TA transporter, this trans-
er does not accept DA.

2) The activity of TA transporter expo-
ially increases with the increase of extra-
lar pH (6.3 - 7.9); The activity of DA
porter exhibits a linear increase when the
um pH is below 7.25, and reaches a
au after pH 7.49.

3) The requirement of activation energy
for the TA transporter appears to be homoge-
nous from 2 to 38 °C ($E_a = 12.9 \text{ kcal}\cdot\text{mol}^{-1}$
and Q_{10} and $Q_{10} = 2.0$); while that for the DA
transporter exhibits biphasic behavior, ie, E_a
 $= 4.12 \text{ kcal}\cdot\text{mol}^{-1}$ and $Q_{10} = 1.25$ ($2.0 -$
 12.7°C) and $E_a = 13.0 \text{ kcal}\cdot\text{mol}^{-1}$ and $Q_{10} =$
 2.0 ($12.7 - 39.0^\circ\text{C}$).

4) Benztropine, imipramine, and
tryptamine are very potent inhibitors for TA
transport but not DA transport indicating the
structural difference between the 2 carriers.

5) Cysteine residue having free thiol
group is necessary for the normal function of
TA transporter in rat hepatocytes. Thiol
group modifiers do not block the transport of
DA, suggesting that this type of amino acid
residue is not essential for the activity of the
DA transporter.

More than 9 signal-transducing G-pro-
teins have been indentified⁽¹⁴⁾, among which
 G_s , and G_i (the stimulatory and the inhibitory
regulatory components of adenylyl cyclase)
are particularly important. Our results show
that F^- $10 - 20 \text{ mmol}\cdot\text{L}^{-1}$ stimulated [³H]DA
transport in hepatocytes (Fig 5). This con-
centration is nearly identical to that (around
 $10 \text{ mmol}\cdot\text{L}^{-1}$) which stimulates glucose trans-
porter through a G-protein modulated mecha-
nism in rat epididymal fat cells⁽¹⁵⁾. As the
concentration rises further, the transport ac-
tivity decreases. We suppose that F^- at low-
er concentrations mainly activates G_s , causing
the transport activity to increase. When the
concentration of F^- increases, G_i is also acti-
vated, inducing the transport activity to de-
crease. The result is in agreement with the
finding that mastoparan inhibited DA trans-
port in hepatocytes (Tab 2). Mastoparan is
more active in stimulating G_i (8 - 10 times)
than G_s (2 times)⁽¹⁷⁾. Thus it is possible that
only the inhibitory effect caused by this

peptide toxin can be seen when both G_s and G_i are involved in regulating the activity of the transport.

In conclusion, a transporter-mediated process is the main mechanism for the uptake of DA in hepatocytes. The carrier responsible for the transport of DA is different from that for the uptake of TA in these cells. Signal transducing G-proteins are probably involved in regulating the DA transporter in rat hepatocytes.

ACKNOWLEDGMENTS This work was supported by the Fonds de la Recherche Scientifique, the Fonds de la Recherche Scientifique Médicale (contrat n° 3.4523.91) and the ASBL Air Escargot.

REFERENCES

- 1 Giros B, Mestikawy SEL, Godinot N, Zheng K, Han H, Teresa YF, Caron MG. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. *Mol Pharmacol* 1992; **42**: 383-90.
- 2 Giros B, Mestikawy SEL, Bertrand L, Caron G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. *FEBS Lett* 1991; **295**: 149-54.
- 3 Brian D, McAdam AJ, Sundram S, Pavey G, Harrison LC, Copolov DL. Identification of a dopamine-binding protein on the membrane of the human platelet. *Biochem J* 1992; **287**: 45-50.
- 4 Shah NS, Burch EA, Yates JD, May DA, Donald AG, Freed JE, Pressley LC. Dopamine uptake by human blood platelets. *Rev Commun Psychol Psychiat Behav* 1980; **5**: 25-35.
- 5 Zhong ZD, Wattiaux-De Coninck S, Wattiaux R. Uptake of tyramine by rat hepatocytes. *Biochim Biophys Acta* 1993; **1176**: 77-82.

- 6 Seglen PO. Preparation of isolated rat liver cells. *Method In Cell Biology* 1976; **13**: 29-83.
- 7 Higashijima T, Uzu S, Nakajima T, Ross E. Mastoparan, a peptide toxin from wasp venom, mimics G-protein-coupled receptors by activating GTP-binding regulatory proteins (G-proteins). *J Biol Chem* 1988; **263**: 6491-4.
- 8 Shibata H, Robinson FW, Benzing CF, Kono T. Evidence that protein kinase C may not be involved in the insulin action on cAMP phosphodiesterase; studies with electroporated rat adipocytes that were highly responsive to insulin. *Arch Biochem Biophys* 1991; **285**: 97-104.
- 9 Kuhar MJ, Sanchez-Roa PM, Wong DF, Dannals RN, Grigoriadis DE, Lew R, Milberger M. Dopamine transporter: biochemistry, pharmacology and imaging. *Eur Neurol* 1990; **30** (Suppl 1): 15-20.
- 10 Gilman AG. G-proteins: transducers of receptor-generated signals. *Annu Rev Biochem* 1987; **56**: 615-60.
- 11 Dale DC, Petersdorf RG. Septic shock in Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, editors. *Harrison's principles of internal medicine*; vol 1. New York: McGraw-Hill Book Company, 1987: 905-91.
- 12 Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In Gilman AG, Goodman LS, Gilman A, Murad F, editors. *Goodman and Gilman's The pharmacological basis of therapeutics*. New York: Macmillan Publ, 1985: 145-80.
- 13 Braunwald E. Heart failure. In Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, editors. *Harrison's principles of internal medicine* vol 1. New York: McGraw-Hill book company, 1987: 474-8.
- 14 Birnbaumer L, Codina J, Mattera R, Yatani A, Scheraga H, Toro MJ, Brown AM. Signal transduction by G-proteins. *Kidney International* 1987; **32** (Suppl 23): 14-30.
- 15 Suzuki Y, Shibata H, Inoue S, Kojima I. Stimulation of glucose transport by guanine nucleotides in permeabilized rat hepatocytes. *Biochem Biophys Res Commun* 1992; **189**: 572-80.